Panos Xaplanteris review the RADIANCE-HTN Study, presented by Ajay Kirtane, an international randomized, sham-controlled clinical trial evaluating the safety and efficacy of renal denervation (RDN) in a population of treatment-resistant hypertensive patients. 

Elad Asher reviews the EROSION III trial, presented by Haibo Jia, which studied whether OCT guidance compared with angiographic guidance only is associated with lower stent rate implantation during pPCI in STEMI patients with non-obstructive stenosis.

This study's results emphasise the strengths and limitations of transcatheter mitral valve implantation (TMVI) as a novel and promising therapy providing predictable elimination of MR in most patients, by S. Ludwig et al.

Analyze this EIJ image to see how surgical aortic bioprostheses with expandable ring technology can significantly enhance future ViV procedures.

The present clinical case highlights some anatomical, functional, and devices-related features which may be used as red flag in the LAAO procedure planning due to prevent PA perforation, a rare but serious complication.

Alex Sticchi provides his take on the PASCAL IID Registry and an initial comparison with the CLASP IID. The trial was presented by Jörg Hausleiter during TCT Congress 2022.

Complex percutaneous coronary intervention (PCI) procedures are dramatically increasing in daily practice. Calcified coronary artery lesions and hostile cardiac anatomy may increase the risk of device dislodgment and/or malposition. In such situations, the use of a snare catheter is pivotal to retrieve and/or reposition the device.

Nicola Ryan reports on the BIOFLOW DAPT trial results presented during the ESC 2023 Congress in Amsterdam by Marco Valgimigli and published in Circulation.

BIOFLOW-DAPT is an open-label randomised trial comparing the safety and efficacy of a biodegradable-polymer sirolimus-eluting stent with a durable-polymer zotarolimus-eluting stent in high-bleeding risk patients...

The 2023 European Society of Hypertension (ESH) guidelines were recently presented at the 32nd annual European Meeting on Hypertension and Cardiovascular Protection and simultaneously published in the Journal of Hypertension.1 While wide parts of the guidelines do not substantially differ from the previous 2018 European Society...

Femoral artery pseudoaneurysm is a known complication following cardiac catheterization. Rarely, expansion of the pseudoaneurysm can occur and is often catastrophic. We describe a unique method employed by our centre to deal with such a complication.

Consult this Twitter case from Ricardo Sanz: an 80-year-old man presenting with inferior STEMI, primary PCI being complicated by the presence of a giant coronary aneurysm in the RCA that hindered the advancement of wires and material towards a small and hidden entry point. Creative off-label...

Luis Ortega Paz provides his take on DAPA-MI - A registry-based randomized trial of dapagliflozin in patient with acute myocardial infarction without diabetes, which was presented by Stefan James at AHA 2023 in Philadelphia.

Pulmonary artery rupture during right catheterization is a serious complication that needs to be solved urgently. The patient can be stabilized by tamponade of the pulmonary artery with the catheter balloon tip, as demonstrated in this image in cardiology.

Luis Ortega provides his take on the SEISMIC-HF I study presented by Liviu Klein at AHA 2024, in Chicago.

Make the most of the insights from Jacob Thomsen Loenborg’s interview with Chiara De Biase and Ali Nazmi Calik’s article to capture the key takeaways from this trial, simultaneously published in the NEJM, presented at the ESC Congress 2024 in London.

The SWISS-APERO is a prospective, investigator-initiated, randomized, multi-center, and clinical trial designed to compare the Amulet and Watchman (2.5 and FLX) devices in a head-to-head fashion.

The main goal of the randomized GUIDE-HF trial was to assess the ability of continuous PAP monitoring to improve outcomes in patients with heart failure NYHA class II-IV and a HF hospitalization within previous 12 months or elevated BNP/NT-proBNP.